New potential agents in treating diabetic kidney disease: The fourth act

Drugs

Volumn 66, Issue 18, 2006, Pages 2287-2298

  Williams, Mark E ^a  

^a JOSLIN DIABETES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALBUMIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; FENOFIBRATE; GLYCOPROTEIN; GLYCOSAMINOGLYCAN; INHIBITOR OF ADVANCED GLYCATION END PRODUCT; METALLOPROTEINASE INHIBITOR; PIRFENIDONE; PLACEBO; PROTEIN INHIBITOR; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; PYRIDOXAMINE; RUBOXISTAURIN; SPP 301; SULODEXIDE; UNCLASSIFIED DRUG; XL 784;

ALBUMINURIA; CLINICAL TRIAL; COST OF ILLNESS; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MEGADOSE; DRUG SAFETY; DYSLIPIDEMIA; FIBROSING ALVEOLITIS; GLOMERULOSCLEROSIS; GLOMERULUS BASEMENT MEMBRANE; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; KIDNEY FAILURE; KIDNEY INJURY; MICROALBUMINURIA; NONHUMAN; PROTEIN EXPRESSION; PROTEINURIA; RENAL PROTECTION; REVIEW; TISSUE INJURY; UNSPECIFIED SIDE EFFECT;

ANIMALIA; RATTUS;

EID: 33846062302     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666180-00002     Document Type: Review

References (100)

1. Caramori ML, Mauer M. Diabetes and nephropathy. Curr Opin Nephrol Hypertens 2003; 12: 273-82
2. Muntner P, Coresh J, Powe NR, et al. The contribution of increased diabetes prevalence and improved myocardial infarction and stroke survival to the increase in treated end-stage renal disease. J Am Soc Nephrol 2003; 14: 1568-77
3. Finne P, Reunanen A, Stenman S, et al. Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA 2005; 294: 1782-7
4. MMWR Weekly. Incidence of end-stage renal disease among persons with diabetes, United States, 1990-2002. Atlanta (GA): Centers for Disease Control and Prevention, 2005 Nov 4; 54 (43): 1097-100
5. System USRD: USRDS 2005. Annual data report: atlas of end-stage renal disease in the Unites States. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2005
6. Gordois A, Scuffham P, Shearer A, et al. The health care costs of diabetic nephropathy in the United States and the United Kingdom. J Diabetes Complications 2004; 18: 18-26
7. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-93
8. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86
9. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53
10. Shichiri M, Kishikawa H, Ohkubo Y, et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23 Suppl. 2: B21-9
11. Parving HH, Smidt UM, Hommel E, et al. Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy. Am J Kidney Dis 1993; 22: 188-95
12. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60
13. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9
14. Schrijvers BF, De Vriese AS, Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 2004; 25: 971-1010
15. Gambaro G, Kinalska I, Oksa A, et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol 2002; 13: 1615-25
16. Lewis E, Lewis J, Hunsicker L. Interim analysis of a pilot trial of sulodexide in type 2 diabetic nephropathy with microalbuminuria [abstract]. J Am Soc Nephrol 2005; 16: 58A
17. Tuttle KR, Anderson PW. A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C beta inhibition. Am J Kidney Dis 2003; 42: 456-65
18. Williams M, Bolton W, Degenhardt T, et al. A phase 2 clinical trial of pyridoxamine (pyridorin) in type 2 and type 2 diabetic patients with overt nephropathy (PYR-206) [abstract]. J Am Soc Nephrol 2003; 14: 7A
19. Varghese Z, Moorhead JF, Ruan XZ. The PPARalpha ligand fenofibrate: meeting multiple targets in diabetic nephropathy. Kidney Int 2006; 69: 1490-1
20. Chen LL, Zhang JY, Wang BP. Renoprotective effects of fenofibrate in diabetic rats are achieved by suppressing kidney plasminogen activator inhibitor-1. Vascul Pharmacol 2006; 44: 309-15
21. Wenzel R, Mann J, Jurgens C, et al. The ETA-selective antagonist SPP301 on top of standard treament reduces urinary albumin excretion rate in patients with diabetic nephropathy [abstract]. J Am Soc Nephrol 2005; 16: 58A
22. Gambaro G, van der Woude FJ. Glycosaminoglycans: use in treatment of diabetic nephropathy. J Am Soc Nephrol 2000; 11: 359-68
23. Ofosu FA. Pharmacological actions of sulodexide. Semin Thromb Hemost 1998; 24: 127-38
24. Ceol M, Gambaro G, Sauer U, et al. Glycosaminoglycan therapy prevents TGF-betal overexpression and pathologic changes in renal tissue of long-term diabetic rats. J Am Soc Nephrol 2000; 11: 2324-36
25. Gambaro G, Venturini AP, Noonan DM, et al. Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy. Kidney Int 1994; 46: 797-806
26. Maxhimer JB, Somenek M, Rao G, et al. Heparanase-1 gene expression and regulation by high glucose in renal epithelial cells: a potential role in the pathogenesis of proteinuria in diabetic patients. Diabetes 2005; 54: 2172-8
27. Shafat I, Vlodavsky I, Ilan N. Characterization of mechanisms involved in secretion of active heparanase. J Biol Chem 2006; 281: 23804-11
28. Xu X, Rao G, Maxhimer J, et al. Mechanism of action of sulodexide-mediated control of diabetic proteinuria: inhibition of heparanase-1 activity [abstract]. J Am Soc Nephrol 2005; 16: 673A
29. Gambaro G, Cavazzana AO, Luzi P, et al. Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. Kidney Int 1992; 42: 285-91
30. Nader HB, Buonassisi V, Colburn P, et al. Heparin stimulates the synthesis and modifies the sulfation pattern of heparan sulfate proteoglycan from endothelial cells. J Cell Physiol 1989; 140: 305-10
31. Caenazzo C, Garbisa S, Ceol M, et al. Heparin modulates proliferation and proteoglycan biosynthesis in murine mesangial cells: molecular clues for its activity in nephropathy. Nephrol Dial Transplant 1995; 10: 175-84
32. Zoja C, Morigi M, Figliuzzi M, et al. Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. Am J Kidney Dis 1995; 26: 934-41
33. Gambaro G, Baggio B. Glycosaminoglycans: a new paradigm in the prevention of proteinuria and progression of glomerular disease. Nephrol Dial Transplant 1996; 11: 762-4
34. Solini A, Vergnani L, Ricci F, et al. Glycosaminoglycans delay the progression of nephropathy in NEDDM. Diabetes Care 1997; 20: 819-23
35. Velussi M, Cernigoi A, Dapas F, et al. Glycosaminoglycans oral therapy reduces macroalbuminuria, blood fibrinogen levels and limb arteriopathy clinical signs in patients with non-insulin dependent diabetes mellitus. Diabetes Nutr Metab 1996; 9: 53-8
36. Poplawska A, Szelachowska M, Topolska J, et al. Effect of glycosaminoglycans on urinary albumin excretion in insulin-dependent diabetic patients with micro- or macroalbuminuria. Diabetes Res Clin Pract 1997; 38: 109-14
37. Solini A, Carraro A, Barzon I, et al. Therapy with glycosaminoglycans lowers albumin excretion rate in non-insulin dependent diabetic patients with macroalbuminuria. Diabetes Nutr Metab 1991; 7: 301-5
38. Dedov I, Shestakova M, Vorontzov A, et al. A randomized, controlled study of sulodexide therapy for the treatment of diabetic nephropathy. Nephrol Dial Transplant 1997; 12: 2295-300
39. Szelachowska M, Poplawska A, Topolska J, et al. A pilot study of the effect of the glycosaminoglycan sulodexide on microalbuminuria in type I diabetic patients. Curr Med Res Opin 1997; 13: 539-45
40. Skrha J, Perusicova J, Pont'uch P, et al. Glycosaminoglycan sulodexide decreases albuminuria in diabetic patients. Diabetes Res Clin Pract 1997; 38: 25-31
41. Sorrenti G, Grimaldi M, Canova N, et al. Glycosaminoglycans as a possible tool for micro- and macroalbuminuria in diabetic patients: a pilot study. J Int Med Res 1997; 25: 81-6
42. US National Institutes of Health. Effect of sulodexide in overt diabetic nephropathy [online]. Available from URL: http://www.clinicaltrials.gov/ct/show/ NCT00130312?order=3 [Accessed 2006 Oct 25]
43. US National Institutes of Health. Effect of sulodexide in early diabetic nephropathy [online]. Available from URL: http://www.clinicaltrials.gov/ct/show/ NCT00130208?order=10 [Accessed 2006 Oct 25]
44. Achour A, Kacem M, Dibej K, et al. One year course of oral sulodexide in the management of diabetic nephropathy. J Nephrol 2005; 18: 568-74
45. Vinik A. The protein kinase C-beta inhibitor, ruboxistaurin, for the treatment of diabetic microvascular complications. Expert Opin Investig Drugs 2005; 14: 1547-59
46. Toyoda M, Suzuki D, Honma M, et al. High expression of PKC-MAPK pathway mRNAs correlates with glomerular lesions in human diabetic nephropathy. Kidney Int 2004; 66: 1101-14
47. He Z, King GL. Can protein kinase C beta-selective inhibitor, ruboxistaurin, stop vascular complications in diabetic patients? Diabetes Care 2005; 28: 2803-5
48. Craven PA, DeRubertis FR. Protein kinase C is activated in glomeruli from streptozotocin diabetic rats: possible mediation by glucose. J Clin Invest 1989; 83: 1667-75
49. Ayo SH, Radnik R, Garoni JA, et al. High glucose increases diacylglycerol mass and activates protein kinase C in mesangial cell cultures. Am J Physiol 1991; 261: F571-7
50. Derubertis FR, Craven PA. Activation of protein kinase C in glomerular cells in diabetes: mechanisms and potential links to the pathogenesis of diabetic glomerulopathy. Diabetes 1994; 43: 1-8
51. Inoguchi T, Sonta T, Tsubouchi H, et al. Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase. J Am Soc Nephrol 2003; 14: S227-32
52. Tuttle KR, Johnson EC, Cooney SK, et al. Amino acids injure mesangial cells by advanced glycation end products, oxidative stress, and protein kinase C. Kidney Int 2005; 67: 953-68
53. Scivittaro V, Ganz MB, Weiss MF. AGEs induce oxidative stress and activate protein kinase C-beta(II) in neonatal mesangial cells. Am J Physiol Renal Physiol 2000; 278: F676-83
54. Malhotra M, Kang B, Cheung S, et al. Angiotensin II promotes glucose-induced activation of cardiac protein kinase C isozymes and phosphorylation of troponin I. Diabetes 2001; 50: 1918-26
55. Thallas-Bonke V, Lindschau C, Rizkalla B, et al. Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway. Diabetes 2004; 53: 2921-30
56. Osicka TM, Yu Y, Lee V, et al. Aminoguanidine and ramipril prevent diabetes-induced increases in protein kinase C activity in glomeruli, retina and mesenteric artery. Clin Sci (Lond) 2001; 100: 249-57
57. Shen GX. Selective protein kinase C inhibitors and their applications. Curr Drug Targets Cardiovasc Haematol Disord 2003; 3: 301-7
58. Xia L, Wang H, Goldberg HJ, et al. Mesangial cell NADPH oxidase upregulation in high glucose is protein kinase C dependent and required for collagen IV expression. Am J Physiol Renal Physiol 2006; 290: F345-56
59. Ziyadeh FN, Sharma K. Overview: combating diabetic nephropathy. J Am Soc Nephrol 2003; 14: 1355-7
60. Hudson BI, Bucciarelli LG, Wendt T, et al. Blockade of receptor for advanced glycation endproducts: a new target for therapeutic intervention in diabetic complications and inflammatory disorders. Arch Biochem Biophys 2003; 419: 80-8
61. Chu S, Bohlen HG. High concentration of glucose inhibits glomerular endothelial eNOS through a PKC mechanism. Am J Physiol (Renal Physiol) 2004; 287: F384-92
62. Jirousek MR, Gillig JR, Gonzalez CM, et al. (S)-l 3-[(dimethylamino) methyl]-10,ll,14,15-tetrahydro-4,9: 16, 21-dimetheno-lH, 13H-dibenzo[e,k] pyrrolo[3,4-; h][l,4,13]oxadiazacyclohexadecene-l,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. J Med Chem 1996; 39: 2664-71
63. Joy SV, Scates AC, Bearelly S, et al. Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications. Ann Pharmacother 2005; 39: 1693-9
64. Barbuch RJ, Campanale K, Hadden CE, et al. In vivo metabolism of [14C]ruboxistaurin in dogs, mice, and rats following oral administration and the structure determination of its metabolites by liquid chromatography/mass spectrometry and NMR spectroscopy. Drug Metab Dispos 2006; 34: 213-24
65. Ishii H, Jirousek MR, Koya D, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996; 272: 728-31
66. Koya D, Jirousek MR, Lin YW, et al. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest 1997; 100: 115-26
67. Koya D, Haneda M, Nakagawa H, et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 2000; 14: 439-47
68. Williams ME, Tuttle KR. The next generation of diabetic nephropathy therapies: an update. Adv Chronic Kidney Dis 2005; 12: 212-22
69. Kitada M, Koya D, Sugimoto T, et al. Translocation of glomerular p47phox and p67phox by protein kinase C-beta activation is required for oxidative stress in diabetic nephropathy. Diabetes 2003; 52: 2603-14
70. Kelly DJ, Chanty A, Gow RM, et al. Protein kinase Cbeta inhibition attenuates osteopontin expression, macrophage recruitment, and tubulointerstitial injury in advanced experimental diabetic nephropathy. J Am Soc Nephrol 2005; 16: 1654-60
71. Tuttle KR, Bakris GL, Toto RD, et al. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 2005; 28: 2686-90
72. The PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes 2005; 54: 2188-97
73. Vinik AI, Bril V, Kempler P, et al. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial. Clin Ther 2005; 27: 1164-80
74. Raj DS, Choudhury D, Welbourne TC, et al. Advanced glycation end products: a Nephrologist's perspective. Am J Kidney Dis 2000; 35: 365-80
75. Heidland A, Sebekova K, Schinzel R. Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis 2001; 38: S100-6
76. Forbes JM, Cooper ME, Oldfield MD, et al. Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol 2003; 14: S254-8
77. Khalifah RG, Chen Y, Wassenberg JJ. Post-Amadori AGE inhibition as a therapeutic target for diabetic complications: a rational approach to second-generation Amadorin design. Ann N Y Acad Sci 2005; 1043: 793-806
78. Williams ME. New therapies for advanced glycation end product nephrotoxicity: current challenges. Am J Kidney Dis 2003; 41: S42-7
79. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-20
80. Hou FF, Ren H, Owen WF, et al. Enhanced expression of receptor for advanced glycation end products in chronic kidney disease. J Am Soc Nephrol 2004; 15: 1889-96
81. Thomas MC, Baynes JW, Thorpe SR, et al. The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Curr Drug Targets 2005; 6: 453-74
82. Voziyan PA, Hudson BG. Pyridoxamine: the many virtues of a maillard reaction inhibitor. Ann N Y Acad Sci 2005; 1043: 807-16
83. Kalousova M, Zima T, Tesar V, et al. Advanced glycation end products in clinical nephrology. Kidney Blood Press Res 2004; 27: 18-28
84. Jerums G, Panagiotopoulos S, Forbes J, et al. Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease. Arch Biochem Biophys 2003; 419: 55-62
85. Sabbatini M, Sansone G, Uccello F, et al. Early glycosylation products induce glomerular hyperfiltration in normal rats. Kidney Int 1992; 42: 875-81
86. Bendayan M. Immunocytochemical detection of advanced glycated end products in rat renal tissue as a function of age and diabetes. Kidney Int 1998; 54: 438-47
87. Youssef S, Nguyen DT, Soulis T, et al. Effect of diabetes and aminoguanidine therapy on renal advanced glycation end-product binding. Kidney Int 1999; 55: 907-16
88. Bolton WK, Cattran DC, Williams ME, et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004; 24: 32-40
89. Abdel-Rahman E, Bolton WK. Pimagedine: a novel therapy for diabetic nephropathy. Expert Opin Investig Drugs 2002; 11: 565-74
90. Williams ME. Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease. Curr Diab Rep 2004; 4: 441-6
91. Jandeleit-Dahm KA, Lassila M, Allen TJ. Advanced glycation end products in diabetes-associated atherosclerosis and renal disease: interventional studies. Ann N Y Acad Sci 2005; 1043: 759-66
92. Voziyan PA, Hudson BG. Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage. Cell Mol Life Sci 2005; 62: 1671-81
93. Pomero F, Molinar Min A, La Selva M, et al. Benfotiamine is similar to thiamine in correcting endothelial cell defects induced by high glucose. Acta Diabetol 2001; 38: 135-8
94. Babaei-Jadidi R, Karachalias N, Ahmed N, et al. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 2003; 52: 2110-20
95. Alderson NL, Chachich ME, Youssef NN, et al. The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int 2003; 63: 2123-33
96. Degenhardt TP, Alderson NL, Arlington DD, et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002; 61: 939-50
97. Kang Z, Li H, Li G, et al. Reaction of pyridoxamine with malondialdehyde: mechanism of inhibition of formation of advanced lipoxidation end-products. Amino Acids 2006; 30: 55-61
98. Stitt A, Gardiner TA, Alderson NL, et al. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 2002; 51: 2826-32
99. Pedchenko VK, Chetyrkin SV, Chuang P, et al. Mechanism of perturbation of integrin-mediated cell-matrix interactions by reactive carbonyl compounds and its implication for pathogenesis of diabetic nephropathy. Diabetes 2005; 54: 2952-60
100. Schaumburg H, Kaplan J, Windebank A, et al. Sensory neuropathy from pyridoxine abuse: a new megavitamin syndrome. N Engl J Med 1983; 309: 445-8